<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Singh B</submitter><funding>NIMH NIH HHS</funding><funding>J. Willard and Alice S. Marriott Foundation</funding><funding>National Institute of Mental Health</funding><funding>Australian Government</funding><funding>NIHR Maudsley Biomedical Research Centre</funding><pagination>22-32</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10794603</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(1)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>To understand treatment practices for bipolar disorders (BD), this study leveraged the Global Bipolar Cohort collaborative network to investigate pharmacotherapeutic treatment patterns in multiple cohorts of well-characterized individuals with BD in North America, Europe, and Australia.&lt;h4>Methods&lt;/h4>Data on pharmacotherapy, demographics, diagnostic subtypes, and comorbidities were provided from each participating cohort. Individual site and regional pooled proportional meta-analyses with generalized linear mixed methods were conducted to identify prescription patterns.&lt;h4>Results&lt;/h4>This study included 10,351 individuals from North America (n = 3985), Europe (n = 3822), and Australia (n = 2544). Overall, participants were predominantly female (60%) with BD-I (60%; vs.</pubmed_abstract><journal>Bipolar disorders</journal><pubmed_title>Patterns of pharmacotherapy for bipolar disorder: A GBC survey.</pubmed_title><pmcid>PMC10794603</pmcid><funding_grant_id>R01MH100125</funding_grant_id><funding_grant_id>R01 MH100125</funding_grant_id><pubmed_authors>Millett CE</pubmed_authors><pubmed_authors>Pham D</pubmed_authors><pubmed_authors>Godin O</pubmed_authors><pubmed_authors>Dubertret C</pubmed_authors><pubmed_authors>Samalin L</pubmed_authors><pubmed_authors>Yocum AK</pubmed_authors><pubmed_authors>Haffen E</pubmed_authors><pubmed_authors>Peters AT</pubmed_authors><pubmed_authors>Vieta E</pubmed_authors><pubmed_authors>Strawbridge R</pubmed_authors><pubmed_authors>Coombes BJ</pubmed_authors><pubmed_authors>Young AH</pubmed_authors><pubmed_authors>Olie E</pubmed_authors><pubmed_authors>Burdick KE</pubmed_authors><pubmed_authors>Tso IF</pubmed_authors><pubmed_authors>Andreassen OA</pubmed_authors><pubmed_authors>Andreazza AC</pubmed_authors><pubmed_authors>Zandi PP</pubmed_authors><pubmed_authors>Biernacka JM</pubmed_authors><pubmed_authors>Aubin V</pubmed_authors><pubmed_authors>Nierenberg AA</pubmed_authors><pubmed_authors>Fullerton JM</pubmed_authors><pubmed_authors>Fico G</pubmed_authors><pubmed_authors>Leboyer M</pubmed_authors><pubmed_authors>Verdolini N</pubmed_authors><pubmed_authors>Schwan R</pubmed_authors><pubmed_authors>Keramatian K</pubmed_authors><pubmed_authors>Frye MA</pubmed_authors><pubmed_authors>Yatham LN</pubmed_authors><pubmed_authors>Singh B</pubmed_authors><pubmed_authors>Sperry SH</pubmed_authors><pubmed_authors>Gard S</pubmed_authors><pubmed_authors>Berk M</pubmed_authors><pubmed_authors>Mitchell PB</pubmed_authors><pubmed_authors>Belzeaux R</pubmed_authors><pubmed_authors>Etain B</pubmed_authors><pubmed_authors>Williams LJ</pubmed_authors><pubmed_authors>FACE-BD Collaborators, The Global Bipolar Cohort Collaborative</pubmed_authors><pubmed_authors>Ashton MM</pubmed_authors><pubmed_authors>Passerieux C</pubmed_authors><pubmed_authors>Overs BJ</pubmed_authors><pubmed_authors>Polosan M</pubmed_authors><pubmed_authors>McInnis MG</pubmed_authors><pubmed_authors>Roberts G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Patterns of pharmacotherapy for bipolar disorder: A GBC survey.</name><description>&lt;h4>Objectives&lt;/h4>To understand treatment practices for bipolar disorders (BD), this study leveraged the Global Bipolar Cohort collaborative network to investigate pharmacotherapeutic treatment patterns in multiple cohorts of well-characterized individuals with BD in North America, Europe, and Australia.&lt;h4>Methods&lt;/h4>Data on pharmacotherapy, demographics, diagnostic subtypes, and comorbidities were provided from each participating cohort. Individual site and regional pooled proportional meta-analyses with generalized linear mixed methods were conducted to identify prescription patterns.&lt;h4>Results&lt;/h4>This study included 10,351 individuals from North America (n = 3985), Europe (n = 3822), and Australia (n = 2544). Overall, participants were predominantly female (60%) with BD-I (60%; vs.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2025-04-21T23:48:56.559Z</modification><creation>2025-04-05T19:19:50.502Z</creation></dates><accession>S-EPMC10794603</accession><cross_references><pubmed>37463846</pubmed><doi>10.1111/bdi.13366</doi></cross_references></HashMap>